Bristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region
To mark the 10th anniversary of its Global Patient Week, Bristol Myers Squibb, a leading global biopharmaceutical company, ...
Bristol, Prime Medicine in deal to develop T-cell therapies
Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.
BioPharma Dive17m
Aktis raises $175M to fuel radiopharma drug development
Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Poseida’s partnerships with Roche and Astellas aim to advance CAR-T therapies. See PSTX stock details and the impact of ...
BBC50s
BBC Radio Bristol Sport
Reporter Martin Evans travels to Wembley with 40 thousand Bristol City Fans.
precisionmedicineonline41m
Prime Medicine Pipeline Prioritization, Licensing Deal With BMS to Fund Operations Into 2026
The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.